ArticleJournal of kidney cancer and VHL2025

First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma.

Micah Ostrowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.